News Releases

Date	Title and Summary	View
Feb 13, 2023	Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
Feb 06, 2023	Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Feb 02, 2023	Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
Jan 27, 2023	Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Jan 24, 2023	Johnson & Johnson Reports Q4 and Full-Year 2022 Results 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%* 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and
Jan 23, 2023	Biosense Webster, Inc. to Highlight Latest Innovations at AF Symposium 2023 Showcasing Breadth of Cardiac Rhythm Portfolio
Jan 18, 2023	Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference
Jan 03, 2023	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2023
Dec 22, 2022	Johnson & Johnson Completes Acquisition of Abiomed
Dec 16, 2022	Janssen Withdraws Application in European Union Seeking Approval of IMBRUVICA® (ibrutinib) for the Treatment of Patients with Untreated Mantle Cell Lymphoma